A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new ...

We have to improve ourselves and make sure that our offering is relevant,' CEO Weber Lo says Weak consumer confidence in ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

Speaking on the sidelines of the World Economic Forum, Vaishnaw said the PM Modi launched a semiconductor policy in January ...

NBTX stock rises following initiation of dosing in a mid-stage NSCLC study evaluating a potential first-in-class ...

The Production Linked Incentive (PLI) scheme has been a cornerstone of India’s manufacturing push, aiming to enhance domestic ...

The French biotech company Nanobiotix announced today that it has dosed the first patient in the CONVERGE study, a Phase 2 ...

Nanobiotix (NBTX) announced that the first patient has been dosed in the CONVERGE study, a Phase 2 randomized controlled clinical trial ...

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand ...

Jan. 9, 2025 — Researchers have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help ...

According to the latest statistics from the American Cancer Society, incidence rates of lung cancer are now higher in women than in men among people younger than 65 years. Overall, though, the news ...

Apart from being one of the biggest deals in the direct-to-consumer (D2C) sector in recent times, this deal also belies a larger trend: of consolidation and alliances between the D2C and FMCG sectors.